Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

NCT04949256 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

864

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Esophageal Squamous Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Lenvatinib
DRUG: Cisplatin
DRUG: 5-FU
DRUG: Oxaliplatin
DRUG: Leucovorin
DRUG: Levoleucovorin
DRUG: Paclitaxel

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]